Table 3.
Weights of comorbidities in all the included studies and percentages of each minor risk factor in studies with only OCC population.
| Study | Comorbidities | PNI | LVI | Multiple Nodes | pT3–T4 | DOI | Close Margins | pN1 | Low Neck Nodes |
|---|---|---|---|---|---|---|---|---|---|
| Fan 2014 [82] |
NE | 50% POCRT 25% PORT |
17% POCRT 8% PORT |
100% POCRT 100% PORT |
53% POCRT 26% PORT |
≥10 mm in 65% POCRT 67% PORT |
32% POCRT 23% PORT |
No patients | 4% POCRT 5% PORT |
| Spiotto 2017 [76] |
Charlson index Well-balanced in POCRT vs. PORT | NE | 10% POCRT 9% PORT |
56% POCRT 36% PORT |
25% POCRT 18% PORT |
≥5 mm in 4% POCRT vs. 8% PORT | NE | 30% POCRT 58% PORT |
NE |
| Fan 2017 [79] |
ECOG 0–1 in 97% POCRT 94% PORT |
62% POCRT 65% PORT |
15% POCRT 6% PORT |
No patients | pT4: 62% POCRT, 65% PORT |
≥10 mm in 75% POCRT 94% PORT | 56% POCRT 74% PORT |
53% POCRT 26% PORT |
NE |
| Chen WC 2016 (subgroup analysis) [78] |
NE | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs | NPE for patients with only minor RFs |
| Patel 2021 [83] |
No comorbidity in 78% of patients | NE | NE | 53% of patients | 100% pT4b | NE | NE | 11% of patients | NE |
| Li 2020 [75] |
Not specified in the study | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 | NPE for patients with only pN2 |
| Lin 2019 [85] |
NE | 49% patients with minor RFs | 6% patients with minor RFs | 13% patients with minor RF | 28% pT3 44% pT4 patients with minor RFs |
≥10 mm, 64% patients with minor RFs | 13% patients with minor RFs |
18% patients with minor RFs | 0.7%patients with minor RF |
| Trifiletti 2017 [77] |
Charlson Index: 0: 78% PORT, 82%POCRT; 1: 17%PORT, 15% POCRT; 2: 4% PORT, 3% POCRT |
NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
| Tasoulas 2021 [86] |
NE | NPE for studies with mixed populations of HN cancers |
NPE for studies with mixed popultions of HN cancers | NPE for studies with mixed popu- lations of HN cancers |
NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
NPE for studies with mixed populations of HN cancers |
NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
| Feng 2017 [80] |
NE | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
| Osborn 2018 [84] |
Charlson Index: 0: 79% PORT, 81% POCRT; 1: 16% PORT, 15% POCRT; 2: 5% PORT, 3% POCRT |
NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
| Chen MM 2018 [81] |
Comorbidities: 0: 37% PORT, 39% POCRT; 1: 10% PORT, 9% POCRT; 2 or +: 2.5% PORT, 2% POCRT |
NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers | NPE for studies with mixed populations of HN cancers |
Legend: NE: not evaluated; NPE: Not possible to extrapolate; RF: Risk factor; HN: head and neck.